Cipla Share Price: The Indian pharmaceutical sector witnessed a significant rally on Friday, April 24, 2026, led by Cipla Limited, which saw its stock price climb over 5% in early trading. Bouncing back from recent volatility, the stock touched an intraday high of ₹1308.40 on the NSE.
The primary driver for this bullish momentum is a fresh “green light” from the US Food and Drug Administration (USFDA), which granted final approval for the company’s generic version of a popular asthma inhaler. This move is expected to significantly deepen Cipla’s footprint in the lucrative US respiratory market.
The “Ventolin” Boost: Strategic Wins in the US Market
The approval, specifically for the generic version of Ventolin HFA, marks a major milestone for Cipla’s US subsidiary. Respiratory medicine has long been a “crown jewel” for the Mumbai-based pharma giant, and this latest nod reinforces its position as a leader in complex inhalation products. Market analysts noted that the timing of the approval is crucial, providing a much-needed tailwind just weeks before the company is scheduled to announce its Q4 FY26 earnings on May 13, 2026. The news triggered a massive surge in delivery volumes, indicating strong conviction from institutional investors rather than mere speculative trading.
New Leadership, New Horizon: The Achin Gupta Era Begins
The stock’s resilience also comes amid a period of internal transition. Effective April 1, 2026, Mr. Achin Gupta has officially taken charge as the Managing Director and Global CEO, succeeding Umang Vohra. Shareholders recently showed overwhelming support for this leadership change through a postal ballot, with over 99% voting in favor of Gupta’s appointment. With a fresh management team and a strategy focused on “Engine 2.0″—centered on innovation and specialty medicine—the company is positioning itself for a new phase of global growth, particularly in the US and South African markets.
Technical Outlook: Support at ₹1200 as Bulls Take Charge
From a technical standpoint, Cipla is currently trading above its 5-day, 20-day, and 50-day moving averages, signaling short-to-medium-term bullishness. While the broader market has faced pressure from rising oil prices and geopolitical tensions, Cipla has emerged as a top gainer, outperforming many of its Nifty 50 peers. Despite the recent jump, the stock still has room to move toward its 52-week high of ₹1673. Investors are now closely watching the ₹1200 support level, which has acted as a critical downside cushion during recent market corrections.